Hainan Shuangcheng Pharmaceuticals Co., Ltd.
Symboli: 002693.SZ
SHZ
5.18
CNYMarkkinahinta tänään
2322.2660
P/E-suhde
-133.5303
PEG-suhde
2.14B
MRK Cap
- 0.00%
DIV Tuotto
Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693-SZ) Tilinpäätöstiedotteet
Tase
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 512.21 | 146 | 77 | 100 | ||||||||||||||
balance-sheet.row.short-term-investments | 447.02 | 133.8 | 55.4 | 94.3 | ||||||||||||||
balance-sheet.row.net-receivables | 144.81 | 41 | 33.1 | 44.6 | ||||||||||||||
balance-sheet.row.inventory | 291.75 | 65.4 | 55.2 | 52.8 | ||||||||||||||
balance-sheet.row.other-current-assets | 0.05 | 0 | 0.1 | 0 | ||||||||||||||
balance-sheet.row.total-current-assets | 948.81 | 252.4 | 165.4 | 197.5 | ||||||||||||||
balance-sheet.row.property-plant-equipment-net | 1849.45 | 471.8 | 504.7 | 541 | ||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.intangible-assets | 668.54 | 164.9 | 156.9 | 134.4 | ||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 668.54 | 164.9 | 156.9 | 134.4 | ||||||||||||||
balance-sheet.row.long-term-investments | 42.28 | 8.8 | 17.3 | 25.9 | ||||||||||||||
balance-sheet.row.tax-assets | 3.67 | 1 | 1 | 0.7 | ||||||||||||||
balance-sheet.row.other-non-current-assets | 53.66 | 12.2 | 9.1 | 8.3 | ||||||||||||||
balance-sheet.row.total-non-current-assets | 2617.6 | 658.6 | 689.1 | 710.2 | ||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.total-assets | 3566.42 | 911 | 854.6 | 907.7 | ||||||||||||||
balance-sheet.row.account-payables | 59.55 | 15.5 | 17.2 | 15.4 | ||||||||||||||
balance-sheet.row.short-term-debt | 774.46 | 205.3 | 0.3 | 55.7 | ||||||||||||||
balance-sheet.row.tax-payables | 23.85 | 12.8 | 7.2 | 6.3 | ||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 167 | 167 | ||||||||||||||
Deferred Revenue Non Current | 30.41 | 7.6 | 8.9 | 10.3 | ||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 12.16 | - | - | - | ||||||||||||||
balance-sheet.row.other-current-liab | 144.47 | 73.6 | 1.8 | 1.5 | ||||||||||||||
balance-sheet.row.total-non-current-liabilities | 42.56 | 10.7 | 179.4 | 180 | ||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.total-liab | 1235.79 | 330.1 | 287.8 | 309.4 | ||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.common-stock | 1662.29 | 414.7 | 412 | 405 | ||||||||||||||
balance-sheet.row.retained-earnings | -1173.2 | -296.2 | -305.2 | -284.6 | ||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 1000.92 | 87.2 | 82.2 | 86 | ||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 600.88 | 307.9 | 292.9 | 286.5 | ||||||||||||||
balance-sheet.row.total-stockholders-equity | 2090.9 | 513.5 | 481.8 | 492.9 | ||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 3566.42 | 911 | 854.6 | 907.7 | ||||||||||||||
balance-sheet.row.minority-interest | 239.74 | 67.4 | 84.9 | 105.4 | ||||||||||||||
balance-sheet.row.total-equity | 2330.63 | 580.9 | 566.8 | 598.3 | ||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 3566.42 | - | - | - | ||||||||||||||
Total Investments | 447.02 | 133.8 | 55.4 | 94.3 | ||||||||||||||
balance-sheet.row.total-debt | 774.46 | 205.3 | 167.3 | 222.7 | ||||||||||||||
balance-sheet.row.net-debt | 709.27 | 193.1 | 145.6 | 216.9 |
Kassavirtalaskelma
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0.93 | -8.5 | -40.8 | -79.9 | ||||||||||||||
cash-flows.row.depreciation-and-amortization | 16.06 | 57.5 | 54.3 | 57.1 | ||||||||||||||
cash-flows.row.deferred-income-tax | 5.29 | -0.4 | 0.4 | 1.2 | ||||||||||||||
cash-flows.row.stock-based-compensation | 8.3 | 6.9 | 7.2 | -1.2 | ||||||||||||||
cash-flows.row.change-in-working-capital | -23.72 | -4.5 | 14.9 | -12.2 | ||||||||||||||
cash-flows.row.account-receivables | -13.83 | -13.8 | 5.4 | 39.8 | ||||||||||||||
cash-flows.row.inventory | -9.89 | -9.9 | -4.8 | -4.3 | ||||||||||||||
cash-flows.row.account-payables | 0 | 19.6 | 13.8 | -48.9 | ||||||||||||||
cash-flows.row.other-working-capital | 0 | -0.4 | 0.4 | 1.2 | ||||||||||||||
cash-flows.row.other-non-cash-items | -5.52 | -25.8 | -12.5 | 24.5 | ||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -0.08 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -39.11 | -33 | -31.6 | -51.6 | ||||||||||||||
cash-flows.row.acquisitions-net | 30.81 | 27 | 21.7 | 53.6 | ||||||||||||||
cash-flows.row.purchases-of-investments | -418.83 | -471 | -256.2 | -637.2 | ||||||||||||||
cash-flows.row.sales-maturities-of-investments | 456.59 | 391.9 | 299.2 | 615.3 | ||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | -51.6 | ||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 29.47 | -85.1 | 33 | -71.5 | ||||||||||||||
cash-flows.row.debt-repayment | -60.74 | -12 | -55.3 | -1.8 | ||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.dividends-paid | -8.7 | -11.1 | -9.1 | -9.8 | ||||||||||||||
cash-flows.row.other-financing-activites | 38.34 | 68.1 | 23.8 | 57 | ||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -31.1 | 44.9 | -40.6 | 45.4 | ||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | -0.02 | 0.1 | -0.1 | -0.3 | ||||||||||||||
cash-flows.row.net-change-in-cash | 1.46 | -14.8 | 15.8 | -36.9 | ||||||||||||||
cash-flows.row.cash-at-end-of-period | 59.79 | 6.8 | 21.6 | 5.8 | ||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 58.33 | 21.6 | 5.8 | 42.7 | ||||||||||||||
cash-flows.row.operating-cash-flow | -0.08 | 25.2 | 23.6 | -10.5 | ||||||||||||||
cash-flows.row.capital-expenditure | -39.11 | -33 | -31.6 | -51.6 | ||||||||||||||
cash-flows.row.free-cash-flow | -39.19 | -7.8 | -8.1 | -62.1 |
Tuloslaskelmarivi
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 259.14 | 274.8 | 320.3 | 269.4 | ||||||||||||||
income-statement-row.row.cost-of-revenue | 77.43 | 88.3 | 81.4 | 60.2 | ||||||||||||||
income-statement-row.row.gross-profit | 181.71 | 186.5 | 238.9 | 209.3 | ||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||
income-statement-row.row.research-development | 14.15 | - | - | - | ||||||||||||||
income-statement-row.row.selling-general-administrative | 14.02 | - | - | - | ||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 115.8 | - | - | - | ||||||||||||||
income-statement-row.row.other-expenses | 71.77 | 63.2 | 69 | 69.7 | ||||||||||||||
income-statement-row.row.operating-expenses | 210.16 | 215.8 | 282.7 | 264.6 | ||||||||||||||
income-statement-row.row.cost-and-expenses | 287.59 | 304.1 | 364.1 | 324.8 | ||||||||||||||
income-statement-row.row.interest-income | 0.1 | 0.1 | 0.1 | 0.1 | ||||||||||||||
income-statement-row.row.interest-expense | 10.15 | 11.2 | 9 | 10 | ||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 115.8 | - | - | - | ||||||||||||||
income-statement-row.row.total-other-income-expensenet | -0.05 | 15.6 | 2 | -25.6 | ||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||
income-statement-row.row.other-operating-expenses | 71.77 | 63.2 | 69 | 69.7 | ||||||||||||||
income-statement-row.row.total-operating-expenses | -0.05 | 15.6 | 2 | -25.6 | ||||||||||||||
income-statement-row.row.interest-expense | 10.15 | 11.2 | 9 | 10 | ||||||||||||||
income-statement-row.row.depreciation-and-amortization | -9.92 | 57.5 | 54.3 | 57.1 | ||||||||||||||
income-statement-row.row.ebitda-caps | -22.8 | - | - | - | ||||||||||||||
income-statement-row.row.operating-income | -12.88 | -24.5 | -42.3 | -53.2 | ||||||||||||||
income-statement-row.row.income-before-tax | -12.93 | -8.9 | -40.4 | -78.8 | ||||||||||||||
income-statement-row.row.income-tax-expense | -8.64 | -0.4 | 0.4 | 1.2 | ||||||||||||||
income-statement-row.row.net-income | 0.93 | -8.5 | -40.8 | -79.9 |
Usein kysytty kysymys
Mikä on Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) taseen loppusumma?
Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) kokonaisvarat ovat 911018789.000.
Mikä on yrityksen vuotuinen liikevaihto?
Vuotuinen liikevaihto on 100763670.000.
Mikä on yrityksen voittomarginaali?
Yrityksen voittomarginaali on 0.701.
Mikä on yrityksen vapaa kassavirta?
Vapaa kassavirta on -0.095.
Mikä on yrityksen nettovoittomarginaali?
Nettovoittomarginaali on 0.004.
Mikä on yrityksen kokonaistulot?
Kokonaisliikevaihto on -0.050.
Mikä on Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) nettovoitto (nettotulos)?
Nettovoitto (nettotulos) on -8496001.960.
Mikä on yrityksen kokonaisvelka?
Kokonaisvelka on 205303152.000.
Mikä on yrityksen toimintakulujen määrä?
Toimintakulut ovat 215787255.000.
Mikä on yrityksen kassan määrä?
Yrityksen kassavarat ovat 3712099.000.